Department of Clinical Research, Tumor Biology Center, Breisacher Strasse 117, 79106, Freiburg, Germany.
Support Care Cancer. 2010 Feb;18(2):159-70. doi: 10.1007/s00520-009-0640-4. Epub 2009 Apr 29.
Advanced tumor disease very often evokes excessive loss of body weight. Among others, fish oil or marine fatty acid ethyl esters were investigated for treatment of cancer cachexia with controversial results. In this study, a new formulation of marine fatty acids was investigated, the marine phospholipids, with more than 50% of phospholipid-bound fatty acids being eicosapentaenoic and docosahexaenoic acid.
Thirty-one tumor patients with various tumor entities suffering from weight loss were asked to take marine phospholipids (1.5 g/day) as softgel capsules for a period of 6 weeks. Compliance, body weight, appetite, and quality of life as well as the fatty acid profile in plasma and blood cells were monitored; 17 patients could be analyzed.
Marine phospholipids were very well accepted; low-dose supplementation resulted in a significant increase of eicosapentaenoic and docosahexaenoic acid in plasma phospholipids; therefore, significantly reducing the n-6 to n-3 fatty acid ratio. A stabilization of body weight was achieved (median weight change of +0.6% after 6 weeks), while appetite and quality of life improved.
These promising first results encourage further investigation of marine phospholipids in cancer care.
晚期肿瘤疾病常导致体重过度下降。为此,人们研究了鱼油或海洋脂肪酸乙酯,以治疗癌症恶病质,但结果存在争议。本研究中,我们考察了一种新型海洋脂肪酸制剂,即海洋磷脂,其 50%以上的磷脂结合脂肪酸为二十碳五烯酸和二十二碳六烯酸。
31 例患有各种肿瘤实体瘤并伴有体重下降的肿瘤患者,被要求服用海洋磷脂(1.5 g/天)软胶囊,为期 6 周。我们对患者的依从性、体重、食欲、生活质量以及血浆和血细胞中的脂肪酸谱进行了监测;其中 17 例患者可进行分析。
海洋磷脂的接受度非常好;低剂量补充可显著增加血浆磷脂中的二十碳五烯酸和二十二碳六烯酸,从而显著降低 n-6 与 n-3 脂肪酸的比例。体重稳定(6 周后体重中位数变化+0.6%),而食欲和生活质量改善。
这些有前景的初步结果鼓励进一步研究海洋磷脂在癌症治疗中的应用。